Discovering the Antecedents of Rheumatoid Arthritis Flare

Overview

Longitudinal study of patients with rheumatoid arthritis comparing measures of disease activity with blood samples.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2025

Detailed Description

80% of patients living with rheumatoid arthritis can expect fluctuations in their symptoms over time. Dramatic increases in disease activity are considered flare. This study will follow patients with increased risk for flare prospectively for one year. Serial questionnaires and disease activity scores will be compared to blood samples to better understand the molecular phenotype of rheumatoid arthritis flares.

Clinical Trial Outcome Measures

Primary Measures

  • RNA transcripts that correlate with rheumatoid arthritis disease activity
    • Time Frame: 1 year
    • Blood drawn at various times throughout one year will be correlated with fluctuations in RA disease activity.

Participating in This Clinical Trial

Inclusion Criteria

  • 2010 criteria for Rheumatoid Arthritis – Swelling of at least one joint and or elevated acute phase reactants – Greater than or equal to 40 years old or less than or equal to 65 year old female sex – cyclic citrullinated peptide antibody + in the past 12 months Exclusion Criteria:

  • hemoglobin < 9 – white blood cell count < 3.5 – Diagnosis of any active malignancy within the last 3 years besides non-melanomatous skin cancer – Diagnosis of diabetes and requires insulin – HIV+, Hep B S Ag+, Hep C polymerase chain reaction + – Untreated latent tuberculosis – Diagnosis of any additional systemic autoimmune connective tissue disease – Inability to reliably complete study requirements – History, physical, social or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the principal investigator, make the candidate ineligible for the study

Gender Eligibility: Female

Minimum Age: 40 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rockefeller University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dana E Orange, MD, MS, Principal Investigator, The Rockefeller University Hospital

References

Orange DE, Yao V, Sawicka K, Fak J, Frank MO, Parveen S, Blachere NE, Hale C, Zhang F, Raychaudhuri S, Troyanskaya OG, Darnell RB. RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares. N Engl J Med. 2020 Jul 16;383(3):218-228. doi: 10.1056/NEJMoa2004114.

Brewer RC, Lanz TV, Hale CR, Sepich-Poore GD, Martino C, Swafford AD, Carroll TS, Kongpachith S, Blum LK, Elliott SE, Blachere NE, Parveen S, Fak J, Yao V, Troyanskaya O, Frank MO, Bloom MS, Jahanbani S, Gomez AM, Iyer R, Ramadoss NS, Sharpe O, Chandrasekaran S, Kelmenson LB, Wang Q, Wong H, Torres HL, Wiesen M, Graves DT, Deane KD, Holers VM, Knight R, Darnell RB, Robinson WH, Orange DE. Oral mucosal breaks trigger anti-citrullinated bacterial and human protein antibody responses in rheumatoid arthritis. Sci Transl Med. 2023 Feb 22;15(684):eabq8476. doi: 10.1126/scitranslmed.abq8476. Epub 2023 Feb 22.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.